Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”) because the identified confidential portions are (i) not material and (ii) would be competitively harmful if publicly disclosed....License and Collaboration Agreement • November 14th, 2023 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Amended and Restated License and Collaboration Agreement (the “Amendment No. 1”) is entered into as of September 12, 2023 (the “Amendment No. 1 Effective Date”) by and among Pieris Pharmaceuticals, Inc., a Nevada corporation located at 225 Franklin Street, 26th floor, Boston, MA 02110 (“PIRS US”) and Pieris Pharmaceuticals GmbH, a company organized and existing under the laws of Germany located at Zeppelinstrasse 3, 85399, Hallbergmoos, Germany (“PIRS Germany” and collectively and together with PIRS US and their Affiliates, “PIRS”), and Seagen Inc., a Delaware corporation located at 21823 30th Drive SE, Bothell, WA 98021 (together with its Affiliates, “SGEN”). SGEN, PIRS US and PIRS Germany are individually referred to herein as a “Party” and collectively, as the “Parties”.
CONSULTING AGREEMENTConsulting Agreement • November 14th, 2023 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Consulting Agreement (the “Agreement”) by and between Pieris Pharmaceuticals, Inc., a Nevada corporation with offices at 225 Franklin Street, Floor 26 Boston, MA 02110 and Pieris Pharmaceuticals GmbH, a German company with offices at Zeppelinstrasse 3, 85399 Hallbergmoos, Germany (collectively, “Pieris”) and Ahmed Mousa located at [***] (“Advisor”) (hereinafter individually a “Party” or collectively the “Parties”) is agreed upon as of the date last signed below and is deemed effective as of September 11, 2023 (the “Effective Date”).
